Accutane (Isotretinoin) Global Regulatory Status

Is isotretinoin approved in the United States?

Yes, with a narrow indication: severe recalcitrant nodular acne in non-pregnant patients 12 years and older with multiple inflammatory nodules 5 mm or larger, reserved for people unresponsive to conventional therapy including systemic antibiotics [1]. FDA lists Absorica, Absorica LD, Claravis, Amnesteem, Myorisan and Zenatane, and notes that Accutane is not currently marketed in the US [4]; the generic isotretinoin label gives 1982 as the initial U.S. approval year [5]. Absorica and Absorica LD are not substitutable on a mg per mg basis because their bioavailability and recommended doses differ [1]. Isotretinoin is available only as FDA-approved capsules through the iPLEDGE REMS, and compounded drugs are not FDA-approved, with FDA not verifying their safety, effectiveness or quality before marketing [1][6].

What does iPLEDGE require?

iPLEDGE began in early 2005, was approved as a REMS in 2010, and is a shared system covering every FDA-approved isotretinoin product [2]. Prescribers and pharmacies must be certified, wholesalers registered, and every patient enrolled, including patients who cannot get pregnant, who must not share the drug or donate blood [1]. For patients who can get pregnant, the Absorica label requires a screening pregnancy test in a medical setting, a confirmatory test at least 30 days later, a test within 7 days before each prescription, and testing after treatment; the prescription must be collected within 7 days of the test, with a maximum 30-day supply and no refills [1].

What changed in 2026, and when does it start?

FDA approved modifications to the iPLEDGE REMS on February 9, 2026 [2][7]. The approved changes let a prescriber permit pregnancy tests outside a medical setting, including at-home tests, during and after treatment; pre-treatment tests must still be done in a medical setting [2]. After a missed 7-day prescription window, a repeat pregnancy test may be done immediately. If treatment has not started, that repeat test must be done in a medical setting [2]. FDA also approved an end to monthly counseling documentation for patients who cannot get pregnant, who are counseled at enrollment, and removal of the 30-day prescription window for those patients [2].

FDA originally scheduled these changes for August 8, 2026. Its iPLEDGE page, current as of June 16, 2026, gives November 15, 2026 as the new planned implementation date [2]. Until the modifications are fully implemented, FDA says it will continue to exercise enforcement discretion on pregnancy testing requirements under its October 2023 update [2]. The Absorica label effective August 19, 2026 already includes the at-home test option [1].

What does the European Union require?

The European Union uses pregnancy-prevention measures for oral isotretinoin, including pregnancy testing, contraception requirements and related product information [3]. EMA completed its review of retinoid medicines on 22 March 2018, and the European Commission issued a final legally binding decision valid across the EU [3]. For isotretinoin, acitretin and alitretinoin, the programme requires pregnancy tests before, during and after stopping treatment, at least one effective method of contraception during and after treatment, an acknowledgement form and a patient reminder card, with a boxed warning on the outer packaging [3]. EMA also added a warning about possible depression, anxiety and mood changes to oral retinoid prescribing information, noting that the data did not clearly establish whether the risk was due to retinoids, and added no such warning for topical retinoids [3].